SCHEMBL1743404

SCHEMBL1743404

Ic1cc2c(cc1I)OCCO2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB2 P05107 1/20 0.43
ICAM1 P05362 1/20 0.43
ITGAL P20701 1/20 0.43
LMNA P02545 3/20 0.39
MAPT P10636 3/20 0.39
HTT P42858 2/20 0.39
BLM P54132 1/20 0.39
KDM4E B2RXH2 3/20 0.38
GAA P10253 2/20 0.38
CRHBP P24387 2/20 0.38
CRHR2 Q13324 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TSHR P16473 2/20 0.37
ALOX5 P09917 1/20 0.37
ADRA2A P08913 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
POLB P06746 1/20 0.34
NPC1 O15118 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31709528 0.81 CYP3A4 (0.44) MAPTGAASMN1; SMN2POLBNPC1
SCHEMBL1742802 0.81 CYP3A4 (0.44) MAPTGAASMN1; SMN2POLBNPC1
SCHEMBL27382541 0.79 ITGB2 (0.53) ITGB2ICAM1ITGALLMNAMAPT
SCHEMBL10341 0.73 LMNA (0.48) ITGB2ICAM1ITGALLMNAMAPT
SCHEMBL29413018 0.73 LMNA (0.48) ITGB2ICAM1ITGALLMNAMAPT
SCHEMBL15982628 0.71 LMNA (0.60) ITGB2ICAM1ITGALLMNAMAPT
SCHEMBL15982613 0.71 LMNA (0.60) ITGB2ICAM1ITGALLMNAMAPT
SCHEMBL15982312 0.71 LMNA (0.60) ITGB2ICAM1ITGALLMNAMAPT
SCHEMBL5768129 0.71 MAPT (0.47) ITGB2ICAM1ITGALLMNAMAPT
SCHEMBL21489522 0.69 ALOX5 (0.58) ITGB2ICAM1ITGALLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119264037-A Method for preparing 3-phenylpyridine from pyridine nitrogen oxide 苏州大学 2025-01-07 CN disclosed
US-20230192687-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2023-06-22 US disclosed
US-11560377-B2 Fused amino pyridine as HSP90 inhibitors Guris, Inc. (US) 2023-01-24 US disclosed
US-20210292317-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2021-09-23 US disclosed
US-10844056-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2020-11-24 US disclosed
US-20200062754-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2020-02-27 US disclosed
US-10428068-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2019-10-01 US disclosed
US-20190010152-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2019-01-10 US disclosed
US-10035797-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2018-07-31 US disclosed
US-20170267674-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2017-09-21 US disclosed
US-8586605-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2013-11-19 US disclosed
EP-2069324-B1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2013-07-31 EP disclosed
US-8324240-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2012-12-04 US disclosed
US-20120237508-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS, INC. 2012-09-20 US disclosed
EP-2387316-A1 FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS Curis, Inc. (US) 2011-11-23 EP disclosed
US-20100184801-A1 FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS CURIS, INC. 2010-07-22 US disclosed
WO-2010083403-A1 FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS CURIS, INC. (US) 2010-07-22 WO disclosed
EP-2069324-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS Curis, Inc. (US) 2009-06-17 EP disclosed
WO-2008115719-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS, INC. (US) 2008-09-25 WO disclosed
US-20080234314-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS, INC. 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190010152-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P ITGB2 4838/4885ICAM1 2692/4885ITGAL 4773/4885
US-10428068-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P ITGB2 4838/4885ICAM1 2692/4885ITGAL 4773/4885
US-20170267674-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P ITGB2 4838/4885ICAM1 2692/4885ITGAL 4773/4885
US-20120237508-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P ITGB2 4838/4885ICAM1 2692/4885ITGAL 4773/4885
US-20230192687-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P ITGB2 4838/4885ICAM1 2692/4885ITGAL 4773/4885
US-20080234314-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P ITGB2 4838/4885ICAM1 2692/4885ITGAL 4773/4885
US-20100184801-A1 FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS IDH2, IDH1, AADAT ITGB2 4243/4885ICAM1 1968/4885ITGAL 2602/4885
US-20210292317-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P ITGB2 4838/4885ICAM1 2692/4885ITGAL 4773/4885
US-20200062754-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P ITGB2 4838/4885ICAM1 2692/4885ITGAL 4773/4885
US-11560377-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P ITGB2 4838/4885ICAM1 2692/4885ITGAL 4773/4885
US-10844056-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P ITGB2 4838/4885ICAM1 2692/4885ITGAL 4773/4885
US-10035797-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P ITGB2 4838/4885ICAM1 2692/4885ITGAL 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.